Annotation Detail for TFE3
Basic Information
Top
| Pathway ID | Pathway Name |
|---|
| 200002 | Regulation of nuclear SMAD2/3 signaling |
| 200027 | E2F transcription factor network |
| Desease ID | Desease Name |
|---|
| Cancers |
| Cancers of soft tissues and bone |
| H00051 | Alveolar soft part sarcoma |
| Desease Name |
|---|
| Renal cell carcinoma, papillary, 1 |
| Chemical ID |
Chemical Name |
Interaction |
Interaction Action |
Publication |
|---|
| D001374 |
Azacitidine |
Azacitidine results in increased expression of TFE3 mRNA | increases expression | 19194470
|
| D016572 |
Cyclosporine |
Cyclosporine results in increased expression of TFE3 mRNA | increases expression | 20106945
|
| D003561 |
Cytarabine |
Cytarabine results in increased expression of TFE3 mRNA | increases expression | 19194470
|
| D004040 |
Dietary Carbohydrates |
Dietary Carbohydrates results in decreased expression of TFE3 mRNA | decreases expression | 17490981
|
| C029938 |
nickel sulfate |
nickel sulfate results in decreased expression of TFE3 mRNA | decreases expression | 16780908
|
| C009131 |
pyrimidin-2-one beta-ribofuranoside |
pyrimidin-2-one beta-ribofuranoside results in increased expression of TFE3 mRNA | increases expression | 19194470
|
| Disease ID |
Disease Name |
Direct Evidence |
Inference Chemical Name |
Inference Score |
Publication |
|---|
| MESH:D055371 |
Acute Lung Injury |
|
nickel sulfate |
4.66 | 16100012 19131640 12718980 11954676 |
| MESH:D002292 |
Carcinoma, Renal Cell |
marker/mechanism |
|
| |
| MESH:D002471 |
Cell Transformation, Neoplastic |
|
Cyclosporine |
7.82 | 12371664 |
| MESH:D002471 |
Cell Transformation, Neoplastic |
|
Cytarabine |
7.82 | 8243401 |
| MESH:D002779 |
Cholestasis |
|
Cyclosporine |
3.14 | 19486331 |
| MESH:D015179 |
Colorectal Neoplasms |
|
Azacitidine |
2.72 | 19934284 |
| MESH:D017449 |
Dermatitis, Allergic Contact |
|
nickel sulfate |
4.08 | 11298694 16823706 16780908 |
| MESH:D005234 |
Fatty Liver |
|
Cyclosporine |
3.18 | 19224547 |
| MESH:D005355 |
Fibrosis |
|
Cyclosporine |
3.56 | 12168785 12639820 |
| MESH:D005885 |
Gingival Hyperplasia |
|
Cyclosporine |
4.68 | 8708960 |
| MESH:D006457 |
Hemoglobinuria, Paroxysmal |
|
Cyclosporine |
4.88 | 15720958 |
| MESH:D006689 |
Hodgkin Disease |
|
Cytarabine |
4.70 | 16200630 |
| MESH:D006973 |
Hypertension |
|
Cyclosporine |
2.19 | 10903974 |
| MESH:D007638 |
Keratoconjunctivitis Sicca |
|
Cyclosporine |
4.96 | 15604871 |
| MESH:D007674 |
Kidney Diseases |
|
Cyclosporine |
2.50 | 8314463 10903974 18776723 |
| MESH:D007680 |
Kidney Neoplasms |
|
Cyclosporine |
3.00 | 12371664 |
| MESH:D007938 |
Leukemia |
|
Azacitidine |
3.83 | 19148494 |
| MESH:D007951 |
Leukemia, Myeloid |
|
Azacitidine |
4.95 | 19077051 |
| MESH:D015470 |
Leukemia, Myeloid, Acute |
|
Azacitidine |
3.04 | 17596541 18720364 |
| MESH:D054429 |
Leukemia, Myelomonocytic, Juvenile |
|
Azacitidine |
5.54 | 19299654 |
| MESH:D008175 |
Lung Neoplasms |
|
Azacitidine |
2.73 | 21224363 |
| MESH:D008545 |
Melanoma |
|
pyrimidin-2-one beta-ribofuranoside |
3.78 | 16505122 |
| MESH:D008664 |
Metal Metabolism, Inborn Errors |
|
Cyclosporine |
5.31 | 16801185 |
| MESH:D009006 |
Monosomy |
|
Azacitidine |
6.60 | 19299654 |
| MESH:D009101 |
Multiple Myeloma |
|
Azacitidine |
4.18 | 19549372 18443271 |
| MESH:D009190 |
Myelodysplastic Syndromes |
|
Azacitidine |
4.16 | 17596541 19805378 18720364 17611569 |
| MESH:D009402 |
Nephrosis, Lipoid |
|
Cyclosporine |
4.96 | 17954296 |
| MESH:D009404 |
Nephrotic Syndrome |
|
Cyclosporine |
3.57 | 18481113 19348381 |
| MESH:D011230 |
Precancerous Conditions |
|
Cyclosporine |
3.51 | 12371664 |
| MESH:D054198 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
|
Cytarabine |
4.60 | 21297632 |
| MESH:D011471 |
Prostatic Neoplasms |
|
Azacitidine |
4.08 | 18324645 |
| MESH:D011565 |
Psoriasis |
|
Cyclosporine |
2.31 | 16882103 |
| MESH:D014605 |
Uveitis |
|
Cyclosporine |
4.50 | 1336536 |
| MESH:D014985 |
Xerophthalmia |
|
Cyclosporine |
4.96 | 17120751 |
Pharmacogenomics Knowledge Base